Article Versions Notes

Mariniello M, Petruzzelli R, Wanderlingh LG, La Montagna R, Carissimo A, Pane F, Amoresano A, Ilyechova EY, Galagudza MM, Catalano F, et al. Synthetic Lethality Screening Identifies FDA-Approved Drugs that Overcome ATP7B-Mediated Tolerance of Tumor Cells to Cisplatin. Cancers. 2020; 12(3):608. https://doi.org/10.3390/cancers12030608

Mariniello, Marta, Raffaella Petruzzelli, Luca G. Wanderlingh, Raffaele La Montagna, Annamaria Carissimo, Francesca Pane, Angela Amoresano, Ekaterina Y. Ilyechova, Michael M. Galagudza, Federico Catalano, and et al. 2020. "Synthetic Lethality Screening Identifies FDA-Approved Drugs that Overcome ATP7B-Mediated Tolerance of Tumor Cells to Cisplatin" Cancers 12, no. 3: 608. https://doi.org/10.3390/cancers12030608

Mariniello, M., Petruzzelli, R., Wanderlingh, L. G., La Montagna, R., Carissimo, A., Pane, F., Amoresano, A., Ilyechova, E. Y., Galagudza, M. M., Catalano, F., Crispino, R., Puchkova, L. V., Medina, D. L., & Polishchuk, R. S. (2020). Synthetic Lethality Screening Identifies FDA-Approved Drugs that Overcome ATP7B-Mediated Tolerance of Tumor Cells to Cisplatin. Cancers, 12(3), 608. https://doi.org/10.3390/cancers12030608